Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-arm, Multi-center Clinical Study of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory Natural Killer/T Cell Lymphoma

NCT04038411 is registered in ClinicalTrials.gov with Mingzhi Zhang as lead sponsor.

NCT NCT04038411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04038411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-arm, Multi-center Clinical Study of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory Natural Killer/T Cell Lymphoma
Lead sponsor
Mingzhi Zhang
Phase
Phase 4
Overall status
Unknown status
Start date
April 1, 2019
Completion date
April 1, 2022
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nk/t cell lymphoma